ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer

PLoS Biology

Volumn 10, Issue 12, 2012, Pages

  Kalyuga, Maria ^a   Gallego Ortega, David ^a   Lee, Heather J ^a   Roden, Daniel L ^a   Cowley, Mark J ^a   Caldon, C Elizabeth ^a   Stone, Andrew ^a   Allerdice, Stephanie L ^a   Valdes Mora, Fatima ^a   Launchbury, Rosalind ^b   Statham, Aaron L ^a   Armstrong, Nicola ^a,c   Alles, M Chehani ^a   Young, Adelaide ^a,d   Egger, Andrea ^a   Au, Wendy ^a   Piggin, Catherine L ^a   Evans, Cara J ^a   Ledger, Anita ^a   Brummer, Tilman ^a,h   Oakes, Samantha R ^a   Kaplan, Warren ^a,e   Gee, Julia M W ^f   Nicholson, Robert I ^f   Sutherland, Robert L ^a,e   Swarbrick, Alexander ^a,e   Naylor, Matthew J ^a,e,g   Clark, Susan J ^a,e   Carroll, Jason S ^b   Ormandy, Christopher J ^a,e   more..

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF BATH   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MYC PROTEIN; PROTEIN ELF5; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; EGFR GENE; ELF5 GENE; FOXA1 GENE; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PROTEIN EXPRESSION;

ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MICE; MODELS, BIOLOGICAL; PHENOTYPE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-ETS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 84871683461     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001461     Document Type: Article

References (38)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Andre F, Pusztai L, (2006) Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3: 621-632.
3. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS, (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43: 27-33.
4. Lee H, Ormandy CJ (2012) Elf5, hormones and cell fate. Trends Endocrinol Metab in press.
5. Gutierrez-Hartmann A, Duval DL, Bradford AP, (2007) ETS transcription factors in endocrine systems. Trends Endocrinol Metab 18: 150-158.
6. Oettgen P, Kas K, Dube A, Gu X, Grall F, et al. (1999) Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes. J Biol Chem 274: 29439-29452.
7. Zhou J, Ng AY, Tymms MJ, Jermiin LS, Seth AK, et al. (1998) A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13-15, a region subject to LOH and rearrangement in human carcinoma cell lines. Oncogene 17: 2719-2732.
8. Lapinskas EJ, Palmer J, Ricardo S, Hertzog PJ, Hammacher A, et al. (2004) A major site of expression of the ets transcription factor Elf5 is epithelia of exocrine glands. Histochem Cell Biol 122: 521-526.
9. Donnison M, Beaton A, Davey HW, Broadhurst R, L'Huillier P, et al. (2005) Loss of the extraembryonic ectoderm in Elf5 mutants leads to defects in embryonic patterning. Development 132: 2299-2308.
10. Hemberger M, Udayashankar R, Tesar P, Moore H, Burton GJ, (2010) ELF5-enforced transcriptional networks define an epigenetically regulated trophoblast stem cell compartment in the human placenta. Hum Mol Genet 19: 2456-2467.
11. Ng RK, Dean W, Dawson C, Lucifero D, Madeja Z, et al. (2008) Epigenetic restriction of embryonic cell lineage fate by methylation of Elf5. Nat Cell Biol 10: 1280-1290.
12. Oakes SR, Naylor MJ, Asselin-Labat M-L, Blazek KD, Gardiner-Garden M, et al. (2008) The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 22: 581-586.
13. Choi YS, Chakrabarti R, Escamilla-Hernandez R, Sinha S, (2009) Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol 329: 227-241.
14. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, et al. (2006) Socs2 and Elf5 mediate prolactin-induced mammary gland development. Mol Endo 20: 1177-1187.
15. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
16. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, et al. (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7: 403-417.
17. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, et al. (2008) Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 9: 591.
18. Prat A, Parker JS, Karginova O, Fan C, Livasy C, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
19. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
20. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
21. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100: 5974-5979.
22. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
24. Merico D, Isserlin R, Stueker O, Emili A, Bader GD, (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5: e13984 doi:10.1371/journal.pone.0013984.
25. Schmidt D, Schwalie PC, Ross-Innes CS, Hurtado A, Brown GD, et al. (2010) A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 20: 578-588.
26. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137.
27. Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, et al. (2009) Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 4: e4710 doi:10.1371/journal.pone.0004710.
28. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10: R93.
29. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
30. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, et al. (2012) FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene In press.
31. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, et al. (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044.
32. Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, et al. (2006) Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Relat Cancer 13: 1085-1099.
33. Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, et al. (2005) Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 171: 717-728.
34. Hilton HN, Kalyuga M, Cowley MJ, Alles MC, Lee HJ, et al. (2010) The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5. Mol Endocrinol 24: 1380-1392.
35. Gray DC, Hoeflich KP, Peng L, Gu Z, Gogineni A, et al. (2007) pHUSH: a single vector system for conditional gene expression. BMC Biotechnol 7: 61.
36. Gregory PA, Hansen AJ, Mackenzie PI, (2000) Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter. Pharmacogenetics 10: 809-820.
37. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, et al. (2009) ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48: 240-248.
38. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.